Curve Biosciences Announces Appointment of Dr. Amit Singal as Chief Medical Officer
Curve Biosciences, a company focused on advancing innovative approaches to whole-body intelligence in healthcare, has announced the appointment of Amit Singal, M.D., as its new Chief Medical Officer. This strategic leadership addition marks an important step as the company continues to build out its clinical development capabilities and advance a pipeline centered on improving outcomes for patients with chronic liver diseases.
Dr. Singal is widely recognized as a leading authority in hepatology, with deep expertise in the clinical management of complex liver conditions such as cirrhosis, hepatocellular carcinoma (HCC), and metabolic dysfunction-associated steatohepatitis (MASH). His work has spanned the full continuum of liver disease care, including prevention, early detection, and treatment, with a particular focus on improving survival outcomes through earlier diagnosis of liver cancer.
In his new role at Curve Biosciences, Dr. Singal will be responsible for shaping the company’s clinical strategy and overseeing the development of its therapeutic and diagnostic programs. His leadership is expected to play a central role in translating the company’s scientific innovations into clinically meaningful solutions that can be deployed in real-world healthcare settings.
Dr. Singal currently serves as Chief of Hepatology at the University of Texas Southwestern Medical Center, where he is also a Professor in the Department of Internal Medicine and a member of the Division of Digestive and Liver Diseases. In addition, he holds the position of Medical Director of the UT Southwestern Liver Tumor Program and occupies the prestigious Willis C. Maddrey, M.D. Distinguished Chair in Liver Disease. These roles reflect his extensive experience in both clinical care and academic research, as well as his leadership in advancing the field of hepatology.
The appointment comes at a time when chronic liver diseases are becoming an increasingly significant global health burden. Conditions such as cirrhosis and liver cancer are often diagnosed at advanced stages, when treatment options are limited and outcomes are poor. One of the major challenges in liver disease management is the lack of effective screening and early detection strategies, particularly in high-risk populations. Curve Biosciences aims to address these challenges by developing innovative tools that leverage advanced data and biological insights to enable earlier intervention.
Ritish Patnaik, Ph.D., CEO and Co-Founder of Curve Biosciences, подчеркнул the importance of Dr. Singal’s expertise in driving the company’s mission forward. He described Dr. Singal as one of the world’s foremost experts in chronic liver disease and highlighted his unique ability to bridge clinical medicine, population health, and translational research. According to Patnaik, this combination of skills will be critical as the company accelerates the development of its programs and works to deliver meaningful improvements in patient outcomes.
Dr. Singal expressed enthusiasm about joining Curve Biosciences and contributing to its mission. He noted that throughout his career, he has been focused on addressing gaps in liver care, particularly in clinical settings where early intervention can make the greatest difference. Despite advances in medical science, many patients with liver disease are still diagnosed at a stage when curative treatments are no longer viable. This reality underscores the urgent need for new approaches that can shift the paradigm toward earlier detection and more effective management.
He emphasized that Curve Biosciences is developing innovative solutions designed to address these unmet needs, and he is eager to help translate scientific discoveries into practical tools that can be integrated into routine clinical practice. By improving early detection and enabling timely intervention, these efforts have the potential to significantly enhance both survival rates and quality of life for patients with liver disease.
Dr. Singal’s academic and professional background further underscores his qualifications for this role. He earned his medical degree from the University of Michigan and completed his residency in internal medicine at the University of Washington. He then pursued advanced training through fellowships in gastroenterology and transplant hepatology at the University of Michigan, equipping him with specialized expertise in the diagnosis and treatment of liver disorders.
He is board certified in both gastroenterology and transplant hepatology by the American Board of Internal Medicine and joined the faculty at UT Southwestern in 2010. Over the years, he has built a distinguished career that combines clinical excellence with a strong commitment to research and education.
A significant portion of Dr. Singal’s research has focused on improving the monitoring and management of patients with liver cirrhosis, particularly in the context of early detection of liver cancer. His work has aimed to identify strategies for diagnosing hepatocellular carcinoma at earlier, more treatable stages, thereby improving patient outcomes. This research has been supported by multiple grants from the National Institutes of Health, reflecting its importance and impact within the scientific community.
Dr. Singal has authored more than 300 peer-reviewed publications, making substantial contributions to the medical literature on liver disease. He is also a frequent invited speaker at national and international scientific conferences, where he shares insights from his research and clinical experience with a global audience of healthcare professionals and researchers.
His contributions have been recognized with numerous awards, including Investigator Awards from the International Liver Cancer Association and the American Gastroenterological Association. He has also received the Blue Faery Award for Excellence in Liver Cancer Research, presented by a leading patient advocacy organization dedicated to raising awareness and supporting individuals affected by liver cancer.
The addition of Dr. Singal to Curve Biosciences’ leadership team reflects the company’s commitment to integrating world-class clinical expertise into its operations. As the company advances its pipeline, his guidance will be instrumental in ensuring that its innovations are aligned with the needs of patients and healthcare providers.
Curve Biosciences’ focus on “Whole-Body Intelligence™” represents a novel approach to understanding and managing complex diseases. By integrating data from multiple biological systems, the company aims to develop more comprehensive and precise solutions for diagnosing and treating conditions such as chronic liver disease. This approach has the potential to transform how these diseases are detected and managed, moving beyond traditional models toward more personalized and proactive care.
In conclusion, the appointment of Dr. Amit Singal as Chief Medical Officer marks a significant milestone for Curve Biosciences. His extensive experience in hepatology, combined with his leadership in clinical research and patient care, positions him to play a key role in advancing the company’s mission. As Curve Biosciences continues to develop innovative solutions for chronic liver disease, Dr. Singal’s contributions are expected to help drive meaningful progress in improving patient outcomes and addressing one of the most pressing challenges in modern healthcare.
About Curve Biosciences
Curve Biosciences is the Whole-Body Intelligence company. Curve has created the first molecular blueprint of the human body by manually curating the world’s largest collection of comprehensively-characterized tissue samples into its Whole-Body Atlas. Trained on the clarity of this atlas, the company’s Whole-Body Intelligence models identify chronic disease states through its Whole-Body Blood Tests earlier and more accurately than other methods. Curve’s mission is to provide doctors the best intelligence for their patients and to alleviate the pain of chronic diseases by anchoring medicine in biological truth. The company is based in San Mateo, CA.
Source Link:https://www.businesswire.com/
